Search Results

You are looking at 111 - 120 of 4,059 items for :

  • Refine by Access: All x
Clear All
Full access

Determinants of Enrollment in Cancer Clinical Trials: The Relationship Between the Current State of Knowledge, Societal Disease Burden, and Randomized Clinical Trial Enrollment

Shane Lloyd, Daniela L. Buscariollo, Cary P. Gross, Danil V. Makarov, and James B. Yu

Given the finite resources for cancer research, understanding the focus of current clinical research efforts and the factors influencing these efforts is important. 1 Ideally, research efforts should be focused on maximizing the potential for

Full access

Introduction to the Cancer Center Cessation Initiative Working Groups: Improving Oncology Care and Outcomes by Including Tobacco Treatment

The Cancer Center Cessation Initiative Coordinating Center and Expert Advisory Panel

Cigarette smoking remains the leading cause of preventable cancer and cancer-related deaths in the United States, responsible for roughly 30% of all cancer deaths, representing more than 150,000 Americans killed by tobacco-caused cancer each year

Full access

Basal Cell and Squamous Cell Skin Cancers Guidelines

Vanderbilt-Ingram Cancer Center

Basal cell and squamous cell skin cancers, collectively known as non-melanoma skin cancers (NMSCS), are the most common skin cancers. More than 1 million cases of NMSC are estimated to be diagnosed each year in the United States and their incidence is rising rapidly. Although rarely metastatic, basal cell and squamous cell cancers can produce substantial local destruction and disfigurement and may involve extensive areas of soft tissue, cartilage, and bone. Updates in the 2007 guidelines include changes to the principles of treatment for both basal cell and squamous cell skin cancers and changes in the consideration of radiotherapy.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Use of Inpatient Palliative Care Services in Patients With Advanced Cancer Receiving Critical Care Therapies

Kah Poh Loh, Maya Abdallah, Meng-Shiou Shieh, Mihaela S. Stefan, Penelope S. Pekow, Peter K. Lindenauer, Supriya G. Mohile, Dilip Babu, and Tara Lagu

Cancer mortality rates have been declining over the past 2 decades, and the observed improvements in survival are partially attributable to advances in treatment options. 1 , 2 Treatment-associated complications and disease progression have led

Full access

An Analysis of Hospital Costs for Childhood Cancer Care

Owen Tan, Deborah J. Schofield, and Rupendra Shrestha

Background Childhood cancers have been reported to use a disproportionate amount of healthcare resources in many countries. 1 The average cost of pediatric cancer hospitalization in 2009 was $40,400 in the United States and was approximately 5

Full access

Outcomes of COVID-19 in Patients With a History of Cancer and Comorbid Cardiovascular Disease

Sarju Ganatra, Sourbha S. Dani, Robert Redd, Kimberly Rieger-Christ, Rushin Patel, Rohan Parikh, Aarti Asnani, Vigyan Bang, Katherine Shreyder, Simarjeet S. Brar, Amitoj Singh, Dhruv S. Kazi, Avirup Guha, Salim S. Hayek, Ana Barac, Krishna S. Gunturu, Corrine Zarwan, Anne C. Mosenthal, Shakeeb A. Yunus, Amudha Kumar, Jaymin M. Patel, Richard D. Patten, David M. Venesy, Sachin P. Shah, Frederic S. Resnic, Anju Nohria, and Suzanne J. Baron

Background COVID-19 caused by the SARS-CoV-2 virus has affected millions of people globally. Early reports have suggested that patients with advanced age and other comorbid conditions, particularly cancer and cardiovascular disease (CVD), face

Full access

Genetic Kidney Cancer Syndromes

Thai H. Ho and Eric Jonasch

Hereditary renal cell carcinoma (RCC) has been estimated to account for 5% to 8% of all RCC cases, and extrarenal manifestations may present as early as 3 years of age ( Table 1 ). 1 , 2 RCC is a diverse set of cancers that originate from the

Full access

Cervical Cancer Screening

Stanford Comprehensive Cancer Center

Cervical carcinoma remains a health issue for women worldwide. Cervical cytology screening is the current method for early detection, and the NCCN Cervical Cancer Screening Clinical Practice Guidelines in Oncology provide direction for evaluating and managing this process, including clarified and revised recommendations on screening techniques and intervals and follow-up of abnormal screening results, including colposcopy. Human papillomavirus (HPV) DNA testing for primary cervical cancer has been approved by the FDA, and HPV DNA testing for high-risk virus types can also be used as a component of both primary screening and workup of abnormal cytology results. Colposcopy, along with colposcopically directed biopsies, has become the primary method for evaluating women with abnormal cervical cytologies. Special considerations for colposcopy performed during pregnancy are also discussed.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Molecular Profiling of Endometrial Cancer From TCGA to Clinical Practice

Amy Jamieson and Jessica N. McAlpine

Endometrial cancer (EC) is the most common gynecologic malignancy in North America, with incidence and mortality rates increasing globally. 1 The majority of patients with EC have low-grade and early-stage disease with favorable outcomes, often

Full access

Colon Cancer

Al B. Benson III, J. Pablo Arnoletti, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Paul F. Engstrom, Peter C. Enzinger, James W. Fleshman Jr., Charles S. Fuchs, Jean L. Grem, James A. Knol, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr., Constantinos T. Sofocleous, Alan P. Venook, and Christopher Willett

NCCN Clinical Practice Guidelines in Oncology for Colon Cancer NCCN Categories of Evidence and Consensus Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based